Introduction {#sec1}
============

As the most widespread inhibitory serotonergic receptor ([@ref35]), the serotonin-1A receptor (5-HT~1A~R) represents a viable target in the treatment of disorders of the brain. However, progress in the development of psychiatric drugs continues to be hindered by the relative inaccessibility of the brain, calling for new techniques to study disorder-relevant proteins and their interactions. More than 50 years have passed since the description of monoaminergic neurons of the central nervous system ([@ref14]) and the discovery of drug agents such as imipramine, reserpine, and monoaminoxidase inhibitors ([@ref13]). In line with the monoaminergic hypothesis of depression ([@ref68]), efficacy of, for example, selective serotonin reuptake inhibitors (SSRIs) has been shown repeatedly ([@ref12]). Furthermore, drugs that block the 5-HT~1A~R seem to increase the effect of SSRIs ([@ref3]). Presynaptic 5-HT~1A~R desensitization or downregulation has been proposed as the underlying mechanism ([@ref6]). However, the efficacy of drugs selective for the 5-HT~1A~R in the treatment of disorders of the brain has not been proven as of yet. Still, research continues to focus on drugs that modulate this receptor subtype ([@ref73]). A more profound knowledge on the topological coexpression of the 5-HT~1A~R with other receptors and cellular proteins would certainly help in this regard.

The 5-HT~1A~R is a g-protein-coupled receptor and the most extensively studied receptor within the group of serotonergic receptors ([@ref65]). In the brain, the 5-HT~1A~R works as a presynaptic autoreceptor on serotonergic neurons in the dorsal and median raphe nuclei, whereas in the limbic system and the cortex, the 5-HT~1A~R predominantly functions as a postsynaptic receptor ([@ref8]). Altogether, receptor signaling is dependent of coupling between different receptors, and receptors and cellular proteins. Recent endeavors using biochemical and genetic assays have strived to better characterize g-protein-coupled receptors and their interacting proteins ([@ref1a]). While interesting, these rarely reflect the native cellular environment nor the topologic (co-)expression in the brain ([@ref71]). The Allen Human Brain Atlas (AHBA), an extensive map of the mRNA transcriptome in the human adult brain derived from six healthy human brains ([@ref23]), was a great development in this regard, allowing for the analysis of gene expression in different cell types and across different brain regions ([@ref23]). Neuroimaging techniques, including positron emission tomography (PET), can offer additional in vivo information about the distribution of predefined molecules, for which radioactive tracers are available.

High correlation of protein distribution measured with PET and mRNA expression of the respective gene was shown for the 5-HT~1A~R ([@ref39]), the metabotropic glutamate receptors 1 and 5 ([@ref44]), and the monoamine oxidase A (MAO-A) ([@ref39]). In an effort to predict mRNA expression of 18 686 genes in the entire human brain, our group recently developed a method based on the microarray data from the AHBA and created whole-brain transcriptomic maps for each gene ([@ref22]).

In the current study, we present an explorative coexpression analysis of aforementioned predicted whole-brain mRNA expression of 18 686 genes and in-house PET-binding potential (BP~ND~) data for the 5-HT~1A~R using a Spearman correlation. This correlation only hints toward topological correlations between tracer binding and mRNA expression of diverse proteins and thus does not allow conclusions on functional or pathological protein--protein interactions. The present analysis can be seen as a gene prioritization approach to reduce the number of genes potentially involved in normal serotonergic functioning that can be tested in in vitro studies in the future and might be relevant as therapeutic targets.

Materials and Methods {#sec2}
=====================

Correlation of mRNA expression intensity and nondisplaceable BP~ND~ for the 5-HT~1A~R is based upon a recently developed prediction model for unbiased whole-brain data ([@ref22]).

PET and mRNA Datasets {#sec3}
---------------------

PET BP~ND~ data were reanalyzed from a previous study ([@ref41]). In this study, data were acquired from 30 healthy subjects (mean age 26.7 ± 6.8 years, 14 females) using a GE Advance PET scanner (Genera Electric Medical Systems, Milwaukee, Wisconsin) for 90 min after application of the selective tracer \[carbonyl-^11^C\]WAY-100635. T1-weighted structural data derived from an MPRAGE sequence on a Medspec 3T MRI scanner (Bruker BioSpin) were used for reconstruction of cortical surfaces in FreeSurfer 6.0. Quantification of BP~ND~ in Montreal Neurological Institute (MNI) space and on the cortical surface was performed using the multilinear reference tissue model ([@ref28]) with the insular cortex set as high-binding and cerebellar white matter as the reference region. The insular cortex was chosen because it represents a high-binding region with particularly stable kinetics and large spatial extent ([@ref67]). This minimizes uncertainties in kinetic modeling and spatial normalization as well as influence from single outlier voxels. The study was approved by the ethics committee of the Medical University of Vienna and all subjects provided written informed consent.

Briefly, the prediction of expression patterns was based on Gaussian process regression (ordinary Kriging) implemented in the R package gstat 1.1--5 ([@ref61]). This entails the analysis of spatial dependence by means of variograms, which allow for the calculation of relative structured variability as a metric for the relative fraction of variance in gene expression between samples explained by their spatial distance. A high regional structured variability may be associated with low randomness or measurement error. The outcome of the prediction method was comprehensive datasets of each gene's expression in three-dimensional MNI space and in FreeSurfer surface space. For a detailed description of the methodology, see Gryglewski et al. ([@ref22]).

Coexpression Analysis {#sec4}
---------------------

For each of the 18 686 genes, Spearman's rho (ρ) was calculated to correlate its predicted mRNA expression intensity (to be found on <http://www.meduniwien.ac.at/neuroimaging/mRNA.html>) and both the BP~ND~ for the 5-HT~1A~R and the predicted mRNA expression intensity of the 5-HT1A-receptor. Correlations were calculated for the left hemisphere of the brain to avoid bias from the relative paucity of samples collected from the right hemisphere in the AHBA. Correlations were carried out vertex-wise in surface space for the cortex and voxel-wise in MNI space for subcortical regions. Genes with a ρ \> 0.7 were considered to be highly coexpressed.

In a next step, a leave-one-out cross validation was performed by correlating observed and predicted mRNA expression for each gene using Pearson's correlation coefficient. Genes with an *r* \> 0.3 were selected in order to discard genes with low validity in prediction reflective of a low signal to noise ratio ([@ref22]).

To further prioritize genes coexpressed with the 5-HT~1A~R, the standard deviation (SD) of each gene across cortical and subcortical regions was used. The SD can be seen as a measure of the distribution of each gene. The SD for the BP~ND~ for the 5-HT~1A~R in cortical regions was calculated as SD = 0.44; in subcortical regions, it was calculated as SD = 2.31. Genes with an *r* \> 0.3 and a ρ \> 0.7 and an SD similar to that of the BP~ND~ of the 5-HT~1A~R, that is, the 90th percentile, were therefore selected to reflect coexpression with the 5-HT~1A~R.

![Predicted whole-brain mRNA expression of the *5-HT~1A~R*, *BDNF*, and *AnxA8* genes in the left cortical hemisphere (top three) and average BP~ND~ PET scans using \[*carbonyl*-^11^C\]WAY-100635 (bottom). mRNA expression intensity is given in units of log2. Left = medial view, right = lateral view.](bhz341f1){#f1}

Gene Ontology Analysis {#sec5}
----------------------

Protein Analysis Through Evolutionary Relationships (PANTHER) enable a functional classification of genes utilizing the gene ontology (GO) tool ([@ref4]). For our GO analysis, we used the *GO complete* annotation set comprising about 45 000 distinct function terms ([@ref52]). We performed an overrepresentation test for cellular components, molecular function, and biological processes using the PANTHER classification system analysis for the genes shown to be highly correlated with the BP~ND~ of the 5-HT~1A~R in cortical and subcortical regions, that is, *r* \> 0.3 and ρ \> 0.7 ([@ref53]). This input list was compared to a reference list using a Fisher's exact test and a false discovery rate (FDR) correction for multiple testing.

Results {#sec6}
=======

Vertex-wise Spearman's rho and a consecutive leave-one-out analysis revealed 199 genes (i.e., predicted whole brain mRNA expression) correlated with the BP~ND~ of the 5-HT~1A~R measured with PET on the surface of the left hemisphere (ρ ≥ 0.7 and *r* \> 0.3, supplementary [tables S1](#sup1){ref-type="supplementary-material"} and [S2](#sup1){ref-type="supplementary-material"}). In subcortical regions, 194 genes were shown to be correlated with the BP~ND~ of the 5-HT~1A~R, when applying the methodology described above (also Supplementary Information). The predicted mRNA expression of the 5-HT~1A~R showed a strong correlation with the BP~ND~ of the 5-HT~1A~R in both cortical (ρ = 0.72) and subcortical (ρ = 0.84) regions. Apart from the 5-HT~1A~R gene, *AnxA8, BDNF, C4orf45, GPRIN1, HMGCR, KIAA1239, PGM2l1, PRSS2*, and *TNFAIP8L1* were shown to be correlated with the BP~ND~ of the 5-HT~1A~R in both cortical ([Fig. 1](#f1){ref-type="fig"}) and subcortical regions.

All genes showing a similar SD (90th percentile) as the BP~ND~ of the 5-HT~1A~R, a ρ \> 0.7 and an *r* \> 0.3 can be found in [Table 1](#TB1){ref-type="table"}.

In the GO analysis, genes highly correlated with the 5-HT~1A~R in cortical regions were found to be overrepresented in axons, the somatodendritic compartment and the plasma membrane bounded cell projection part of the data category cellular components (FDR corrected, *P* \< 0.05; [Table 2](#TB2){ref-type="table"}). For subcortical regions, the GO analysis revealed a significant overrepresentation of genes in the data categories of biological processes, that is, neuronal development, and cellular component, that is, in the axon, the presynapse and the cytoplasmic vesicle (also in [Table 2](#TB2){ref-type="table"}).

Discussion {#sec7}
==========

In this exploratory analysis, we found 199 genes in cortical regions and 194 genes in subcortical regions associated with the 5-HT~1A~R using a correlation of predicted whole-brain mRNA expression of 18 686 genes and the BP~ND~ of the 5-HT~1A~R. With our in silico approach, we could reduce the number of genes potentially coexpressed with the 5-HT~1A~R to approximately 1% of the initial data set. When additionally including the SD of the BP~ND~ of the 5-HT~1A~R, only 0.1% of the genes remained. The mRNA of the 5-HT~1A~R was always among the 0.1--1% of genes shown to be highly correlated with the BP~NP~ of the 5-HT~1A~R, hinting toward a validity of our approach to define coexpression and prioritize genes with a shared function or intersecting secondary pathways.

The analysis at hand represents a correlation of the BP~ND~ of the tracer \[*carbonyl*-^11^C\]WAY-100635 with the whole-brain mRNA expression of the 18 686 genes. WAY-100635 binds the 5-HT~1A~R with high affinity and selectivity ([@ref20]; [@ref38]). Chemel et al. ([@ref9]) challenged the initial data of a 100-fold greater selectivity of WAY-100635 to bind the 5-HT~1A~R ([@ref16]). In a follow-up study, Martel et al. ([@ref47]) could, however, show a 200-fold greater selectivity of WAY-100635 to bind the 5-HT~1A~R in comparison with, for example, the Dopamin-D4 receptor. Furthermore, the metabolism of \[*carbonyl*-^11^C\]WAY-100635 does not lead to radiolabelled WAY-100634, which would bind the Dopamin-D4 receptor. Also, based on the low expression of D4 receptor mRNA in the cortex, we do not expect a relevant influence on binding potentials in this region ([@ref49]). Martel et al. concluded that \[*carbonyl*-^11^C\]WAY-100635 specifically antagonizes the 5-HT~1A~R if adequate doses and concentrations are used. Previous studies have yielded inconsistent results on sex differences in 5-HT~1A~R binding ([@ref60]; [@ref32]; [@ref74]; [@ref55]). Parsey et al. ([@ref60]) found significantly higher BP in females compared to males using \[*carbonyl*-^11^C\]WAY-100635. In a previous publication including the current sample, we did not find any sex differences in 5-HT~1A~R binding ([@ref74]). Not only the differences in the modeling methods but also the age and effects of hormonal status could underlie the diverging results. However, the analysis of sex differences in the correlation of PET and mRNA data is primarily limited by the fact that only one of the six brain donor brains was female. Therefore, there are too few samples to create a comprehensive atlas based exclusively on microarray data from the female brain using our method ([@ref22]).

It must be pointed out that the distribution of mRNA expression throughout the brain might differ from protein density and radioligand-binding sites. The 5-HT~1A~R gene is intronless and the mRNA does not undergo mRNA editing or alternative mRNA splicing ([@ref40]). The gene is highly expressed in the hippocampus, the septum, the raphe nuclei, the neocortex, and the hypothalamus ([@ref27]). On a cellular level, apart from serotonergic neurons, the 5-HT~1A~R is also expressed in pyramidal neurons assumed to be glutamatergic in prefrontal and limbic regions ([@ref58]) and in a GABAergic interneuron subpopulation in the prefrontal cortex ([@ref15]). On both serotonergic and nonserotonergic neurons, the 5-HT~1A~R is localized predominantly somatodendritically. In line with our results, studies in rats, monkeys, and the human brain have demonstrated a comparable distribution of the 5-HT~1A~R mRNA and radiolabelled binding sites as well as the receptor protein ([@ref40]). The genes found to correlate highly with the 5-HT~1A~R on the cortical surface also showed an overrepresentation in the GO analysis for the somatodendritic compartment (including the 5-HT~1A~R, the 5-HT~2C~R and BDNF), as well as the axon and the plasma membrane bounded cell projection.

###### 

Genes with an SD closest to the BP~ND~ of the 5-HT~1A~R (90th percentile) and a Spearman rho \>0.7 on the left cortical surface and in subcortical regions

                Gene name                                                                                 Entrez ID   RSV (%)   SD     Spearman (BP~ND~ vs. mRNA)   Spearman (mRNA vs. mRNA)
  ------------- ----------------------------------------------------------------------------------------- ----------- --------- ------ ---------------------------- --------------------------
  Cortical                                                                                                                                                          
                5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled                            3358        66.51     0.53   0.71                         0.86
                5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled                            3350        67.48     0.52   0.72                         1.00
                Atonal homolog 7 (Drosophila)                                                             220 202     72.00     0.52   0.70                         0.89
                Lymphocyte antigen 6 complex, locus H                                                     4062        77.24     0.49   0.71                         0.87
                Natriuretic peptide A                                                                     4878        59.83     0.49   0.75                         0.82
                Copine VI (neuronal)                                                                      9362        90.31     0.45   0.71                         0.92
                Annexin A8                                                                                653 145     60.95     0.44   0.73                         0.84
                ATP/GTP binding protein-like 1                                                            123 624     55.65     0.44   0.76                         0.82
                Kinocilin                                                                                 148 930     41.33     0.43   0.71                         0.87
                v-myb myeloblastosis viral oncogene homolog (avian)                                       4602        50.57     0.42   0.76                         0.85
                Complement factor D (adipsin)                                                             1675        67.41     0.42   0.71                         0.77
                Serine-rich and transmembrane domain containing 1                                         400 120     52.13     0.41   0.75                         0.80
                Tumor protein p53 inducible protein 11                                                    9537        61.40     0.41   0.76                         0.83
                TAF7-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 50 kDa     54 457      53.73     0.40   0.79                         0.88
                Myb/SANT-like DNA-binding domain containing 1                                             345 222     60.97     0.37   0.72                         0.78
                Tumor necrosis factor receptor superfamily, member 11a, NFKB activator                    8792        42.48     0.36   0.71                         0.72
                Protocadherin 19                                                                          57 526      64.88     0.35   0.76                         0.85
                Centromere protein W                                                                      387 103     75.54     0.35   0.75                         0.85
                Sosondowah ankyrin repeat domain family member A                                          134 548     65.79     0.34   0.74                         0.90
                Glycoprotein (transmembrane) nmb                                                          10 457      43.02     0.34   0.72                         0.74
  Subcortical                                                                                                                                                       
                Neuronal differentiation 2                                                                4761        84.80     2.13   0.81                         0.90
                Neuronal differentiation 6                                                                63 974      93.73     2.05   0.71                         0.74
                Cholecystokinin                                                                           885         56.95     1.73   0.80                         0.85
                Complement component 1, q subcomponent-like 3                                             389 941     61.07     1.67   0.71                         0.84
                Brain-derived neurotrophic factor                                                         627         52.91     1.65   0.70                         0.83
                Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7   57 030      76.39     1.57   0.79                         0.86
                LY86 antisense RNA 1 (non-protein coding)                                                 285 780     91.99     1.56   0.75                         0.75
                KIAA1239                                                                                  57 495      63.17     1.50   0.82                         0.93
                Transmembrane protein 200A                                                                114 801     50.43     1.37   0.75                         0.79
                Calsyntenin 2                                                                             64 084      77.86     1.31   0.74                         0.91
                Neuronal pentraxin receptor                                                               23 467      78.11     1.29   0.74                         0.90
                Tumor necrosis factor, alpha-induced protein 8-like 3                                     388 121     47.62     1.25   0.75                         0.89
                T-box, brain, 1                                                                           10 716      91.91     1.21   0.77                         0.82
                5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled                            3350        46.63     1.19   0.85                         1.00
                Meis homeobox 3                                                                           56 917      69.41     1.14   0.75                         0.85
                Nephroblastoma overexpressed                                                              4856        69.43     1.11   0.74                         0.82
                Harakiri, BCL2 interacting protein (contains only BH3 domain)                             8739        84.52     1.10   0.71                         0.87
                Transmembrane protein 155                                                                 132 332     79.31     1.09   0.70                         0.73

Note: RSV, regional structural variability.

###### 

Overrepresented genes on the left cortical hemisphere and in subcortical regions

                         GO ID        GO term                                        Count   *P* value   Genes
  ---------------------- ------------ ---------------------------------------------- ------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cortical                                                                                               
  Cellular component                                                                                     
                         GO:0030424   Axon                                           17      \<0.01      EXOC6, CPLX3, GPM6A, CORO1A, SNCA, TRPV2, NPTX2, CD200, STX1A, BDNF, NECAB2, PTPRO, GPRIN1, CPNE6, U47924, AP3B2, EPHA5
                         GO:0120038   Plasma membrane bounded cell projection part   30      0.04        KNCN, EXOC6, HTR2C, RILPL2, CPLX3, GPM6A, SNCA, PRPH2, U47924, TRPV2, GRM1, NPTX2, AC092324, MPP2, SYTL1, CYP46A1, JPH4, RSPH9, B9D1, CYS1, BDNF, NECAB2, C2orf39, DCDC2, HTR1A, PTPRO, GPRIN1, CPNE6, AP3B2, EPHA5
                         GO:0036477   Somatodendritic compartment                    21      0.03        KNCN, HTR2C, GPM6A, SNCA, U47924, PYCARD, GRM1, NPTX2, MPP2, CD200, CYP46A1, JPH4, CYGB, BDNF, NECAB2, U47924, HTR1A,PTPRO, CPNE6, EPHA5, RTN4RL1
  Subcortical                                                                                            
  Biological process                                                                                     
                         GO:0048666   Neuron development                             23      0.02        NEUROD2, NTNG2, CCK, RAPH1, POSTN, WDR5, MAP6, C1QL1, PAX2, ST7, HCN1, TBC1D24, VSTM2L, NPTXR, SYN1, EMX1, BDNF, MAP2, NOV, GPRIN1, NCAM2, RTN4RL2, HPRT1
  *Cellular component*                                                                                   
                         GO:0030424   Axon                                           20      \<0.01      NTNG2, CCK, PRKAA2, NOV, MAP6, C1QL1, HCN1, TBC1D24, AP3M2, KIF21B, VSTM2L, NPTXR, DYNLL1, SYN1, BDNF, MAP2, GPRIN1, NCAM2, SLC17A7, RTN4RL2
                         GO:0098793   Presynapse                                     16      0.02        NTNG2, CCK, CADPS2, PFN2, CDH10, C1QL1, CADM3, TBC1D24, SYN1, BDNF, DENND1A, PPFIA2, SLC17A7, DNAJC5, STXBP5, LIN7C
                         GO:0031410   Cytoplasmic vesicle                            42      0.01        AC011479, RRAGB, SLC39A2, CADPS2, HYOU1, USP10, UBQLN2, RAB2A, ASTN1, MAP6, ANXA8, SLCO4C1, RAB12, CLIP3, CHGB, TBC1D24, AP3M2, TOLLIP, RFTN1, KIF21B, MALL, RNF11, PRSS3, DYNLL1, TECPR1, PDCD6, PRSS2, LYZL4, SYN1, SPRED2, BDNF, EGF, DENND1A, PGRMC1, KLK7, CNIH3, ATP6V1D, SLC17A7, DNAJC5, STXBP5, JAK3, DBH

All *P*-values FDR corrected with *P* \< 0.05.

Among the 10 genes correlating highly with the BP~ND~ of the 5-HT~1A~R in both cortical and subcortical regions were *Anxa8* and *BDNF*. BDNF has been repeatedly connected to psychiatric disorders such as schizophrenia, bipolar disorder, depression, and addiction ([@ref5]) and the action of psychopharmacologic drugs. Long-term antidepressant therapies such as SSRIs, tricyclic antidepressants, and electroconvulsive therapy seem to induce increased BDNF mRNA ([@ref5]) and protein expression, and infusion of BDNF into the rat hippocampus has been shown to have antidepressant-like effects ([@ref70]). Also, infusions of ketamine, a noncompetitive NMDA-receptor antagonist recently approved as a rapid acting antidepressant, seem to increase BDNF protein levels in the rat hippocampus ([@ref18]). The BDNF gene codes for a neurotrophin called brain-derived neurotrophic factor, which exists as prepro-BDNF and can be cleaved into pro-BDNF and mature BDNF ([@ref43]). Pro-BDNF and mature BDNF seem to have different effects on intracellular signaling pathways ([@ref50]). The mature BDNF unfolds its action through its high-affinity receptor tropomyosin-related kinase B (TrkB) ([@ref5]). Upon binding, intracellular signaling cascades are activated, including the phospholipase-Cγ pathway, the phosphatidyl-inositol 3-kinase pathway, and the MAPK/ERK pathway. Through these pathways, BDNF plays an important role in axonal growth, synaptic plasticity ([@ref79]), and learning and memory ([@ref45]). It is further involved in the proper functioning of GABAergic, glutamatergic, dopaminergic, and serotonergic neurons ([@ref63]). The neurotrophin also appears to influence the morphological differentiation of serotonergic neurons ([@ref48]). Galter and Unsicker ([@ref17]) have shown that serotonin upregulates BDNF expression through 5-HT~1A~R-activation and thereby induces promotion and maintenance of differentiated serotonergic neurons in the rat raphe nucleus. It has been proposed that this promotion of the 5HT-phenotype is mediated through a 5-HT~1A~R-induced downregulation of the cAMP-dependent protein kinase A and the activation of the BDNF/TrkB pathway. In BDNF knockout mice, Hensler et al. ([@ref24]) demonstrated a reduced 5-HT~1A~R function in the dorsal hippocampus compared to control mice. On the other hand, Trajkovska et al. ([@ref76]) did not observe changes in 5-HT~1A~R levels in mouse hippocampal neurons upon short- or long-term exposure with BDNF. Also Vaidya et al. ([@ref77]) found no effect of 5-HT~1A~R agonism on BDNF mRNA levels in the hippocampus and neocortex. One explanation might be the agonist used, which also activates 5-HT~7~R that has opposing effects to the 5-HT~1A~R. In general, however, the topological correlation of the BDNF and 5-HT~1A~R mRNA expression levels observed in this analysis may reflect the known interaction of BDNF with the serotonergic, and especially the 5-HT~1A~R, system ([@ref64]) and could be explained through second messenger cascades such as TrkB and downstream signaling.

The *AnxA8*-gene codes for Annexin A8 that forms part of a family of Ca^2+^-regulated phospholipid-binding proteins ([@ref19]) that is involved in intracellular processes including cell differentiation, proliferation, and receptor signaling and trafficking ([@ref21]; [@ref54]). AnxA8 has been connected to plastic changes of premotor neurons in macaque monkeys following a unilateral lesion of the lateral corticospinal tract ([@ref25]) and has therefore been named a plasticity-related gene. Up until now, to the best of our knowledge, no study has focused on the topological distribution or neuronal gene expression of *AnxA8* in the human brain or its topological coexpression with the 5-HT~1A~R. Previous studies reported on an *AnxA8* expression restricted to certain tissue types, including the skin, lung, liver, and kidney ([@ref62]; [@ref66]). Few studies exist regarding AnxA8 and its role in neuropsychiatric research. Kashem et al. ([@ref34]) have shown increased AnxA8 protein expression in risperidone-treated neural stem cells in comparison with haloperidol. Furthermore, Park et al. ([@ref59]) have implicated AnxA8 as an activity-regulated gene during long-term potentiation in mice. As a protein that affects the cytoskeleton, AnxA8 could interact with the 5-HT~1A~R in the process of dendritic maturation ([@ref78]) or be involved in the regulation of internalization and intracellular movement of the 5-HT~1A~R through Ca^2+^-mediated mechanisms, as is the case for the epidermal growth factor receptor ([@ref19]).

Regarding subcortical regions, the GO analysis revealed overrepresentation of 23 genes involved in the biological process of neuronal development ([Table 2](#TB2){ref-type="table"}), including *NeuroD2*. Apart from a high correlation with the BP~ND~ of the 5-HT~1A~R (ρ = 0.81), *NeuroD2* also showed a similar SD (SD = 2.13) as the BP~ND~ of the 5-HT~1A~R. Alterations in *NeuroD2* have been linked to schizophrenia, where patients with *NeuroD2* polymorphisms showed reduced cognitive functions ([@ref72]). The neuronal differentiation family (*NeuroD1*, *NeuroD2*, *NeuroD4*, *NeuroD6*) represents genes that code for neurogenic basic-helix-loop-helix transcription factors. These factors contribute to premature cell cycle arrest and lead to a mature neuronal phenotype by inducing specific gene transcription. Throughout adulthood, these NeuroD transcription factors remain expressed in postmitotic neurons ([@ref57]). In recent years, they have been connected to the survival of a subset of midbrain dopaminergic neurons in the ventral midbrain ([@ref37]) and to amacrine cell subtype identity in the retina ([@ref11]; [@ref36]). Further, they have been implicated in long-range axogenesis of callosal connections ([@ref7]) and a decrease of neuronal excitability in cortical pyramidal neurons ([@ref10]). Moreover, NeuroD2 has been suggested to regulate trophic factors such as BDNF by showing decreased expression of *BDNF* in NeuroD2-null mice cerebella ([@ref57]). This decrease in expression could potentially also affect 5-HT~1A~R-mRNA expression. Various factors influencing the regulation of 5-HT~1A~R-mRNA expression have been defined including REST, Freud-1, Freud-2, as well as allele-specific factors, such as Deaf1 ([@ref1]). A direct involvement of the NeuroD gene family in the expression of the 5-HT~1A~R has not been shown up until now. In support of our findings, *NeuroD2* is also expressed in cortical and hippocampal pyramidal neurons and granule cells in the dentate gyrus ([@ref69]) and remains expressed in these fully differentiated neuronal subtypes in the adult brain. The proposed coexpression of *NeuroD2* with the 5-HT~1A~R might also reflect the shared inhibitory effects on pyramidal firing. Also, *NeuroD2* could contribute to the 5-HT~1A~R functions of increased neurogenesis and synaptogenesis ([@ref80]).

Implications and Future Directions {#sec8}
==================================

A dysregulation in processes connected to neuronal development is thought to be one of the underlying causes of psychiatric disorders ([@ref42]). In general, the involvement of abovementioned genes reflects the complexity of 5-HTR1A functioning. Using the AHBA, the mRNA expression of the 5-HT~1A~R has been compared to the BP~ND~ of the 5-HT~1A~R ([@ref39]) and to other GPCRs ([@ref30]). Even though we could not validate the results of, for example, Janusonis ([@ref30]) or Sokolina et al. ([@ref71]), the current analysis represents one further attempt in the rapidly growing field of imaging transcriptomics ([@ref2]) to define new functional groups of 5-HT~1A~R signaling. Rather than simple correlations of gene expression that highlight potential functional interactions, future studies should consider the interactions of multiple similarly expressed genes to better reflect the structural composition of a given brain region. For that purpose, unbiased hierarchical clustering approaches have been proposed ([@ref31]). Future coexpression analyses could also include other targets for which radiotracers are available, including the MAO-A, serotonin transporter, and serotonin-2A receptor ([@ref39]) as well as autoradiography data.

Limitations {#sec9}
===========

As the analysis is based on the AHBA and PET imaging, the results are influenced by the underlying data and the respective data processing choices ([@ref2]). Regarding the tracer used, the selectivity of \[*carbonyl*-^11^C\]WAY-100635 has been shown ([@ref47]). However, the use of the drug-binding site for the correlation could have confounded our results, since it might differ from protein density and be influenced by conformational states. Regarding the AHBA data, it comprises a relatively small sample of six specimens with a great diversity of age, sex, and postmortem intervals that could have impacted the transcriptomic profile obtained. Data from the BrainSpan atlas, for example, show differential expression of two exons of the *NeuroD6* gene across the life span ([@ref46]). The samples analyzed comprise human postmortem microarray probes of a specific gene. It has been suggested that the variability of protein levels can only be explained up to 40% by mRNA levels, with a great impact of translation and post-translational modifications ([@ref31]). BDNF, for example, represents the mature protein of the *BDNF* gene. However, the transcript can undergo alternative splicing and several precursors, such as prepro-BDNF and pro-BDNF exist. These subtleties are not taken into account by the AHBA data and the current analysis and would require further work, especially since pro-BDNF and BDNF seem to have opposing effects on neurite growth ([@ref64]). Moreover, investigations of the exon-level transcriptome have revealed spatiotemporal differences in gene expression, especially before birth ([@ref33]). Sun et al. ([@ref75]), for example, have shown asymmetric expression of *NeuroD6* in embryonic human brains. These differences seem to normalize with age ([@ref33]). The genetic mosaicism, a concept that has gained attention in recent years ([@ref29]; [@ref51]; [@ref56]), could, however, potentially affect the generalizability of our results. Furthermore, the 5-HT~1A~R can be present not only on excitatory principal neurons but also on inhibitory interneurons ([@ref42]) and has been shown to be present in cultured astrocytes ([@ref26]), a specification that our analysis did not take into account, that could, however, be relevant for differences in gene expression. To improve comparability and sample quality, multiple samples from various cortical and subcortical areas at identical sites and from both hemispheres across subjects would be necessary. Recent technological advances such as next generation sequencing and single-cell whole genome amplification could help in this regard.

Conclusion {#sec10}
==========

In conclusion, we have correlated predicted whole-brain transcriptomic data from the AHBA with PET data of the 5-HT~1A~R binding to define genes potentially coexpressed with this receptor. The strong correlation between the predicted mRNA expression and the BP~ND~ of the 5-HT~1A~R in cortical and subcortical regions supports the employed methodology. Using our in silico approach, we consolidated the association of "BDNF" and the 5-HT~1A~R and further implicated new genes in serotonergic functioning. Correlating the predicted whole-brain mRNA expression of almost 19 000 genes with the BP~ND~ of the 5-HT~1A~R can be seen as a gene prioritization approach to generate new hypotheses and scientific questions. Given the available data and using computational models, we have reduced the number of genes potentially coexpressed with the 5-HT~1A~R to guide future endeavors to analyze protein interactions, better describe disease pathomechanisms, and lead to new drug targets.

Funding {#sec12}
=======

Austrian Science Fund (FWF P 27141 to R.L.); Austrian National Bank (OENB P11468 to R.L); Hochschuljubilaeumsstiftung of the City of Vienna (to R.S.); Austrian Science Fund (FWF, DOC 33-B27 to M.M.). The funding sources had no further role in the study design, the collection, analysis and interpretation of data, in the writing of the report nor in the decision to submit the paper for publication.

Notes {#sec13}
=====

We thank the staff and the diploma students of the Neuroimaging Lab (NIL) at the Department of Psychiatry and Psychotherapy for clinical, scientific, technical, and administrative support. Also, we would like to thank the staff at the Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, for technical support.

Author Contribution {#sec14}
===================

Without any relevance to this work, S.K. received grants/research support, consulting fees, and/or honoraria within the last 3 years from Angelini, AOP Orphan Pharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd and Takeda. R.L. received conference speaker honorarium within the last 3 years from Shire and research support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of BM Health GmbH since 2019. Without relevance to this work, W.W. received research grants within the last 3 years from Scintomics, Ipsen Pharma, EZAG, and ITG and is a part-time employee of CBmed Ltd, a PPP research center of excellence. All other authors have no biomedical financial interests to disclose and report no potential conflicts of interest. Preliminary findings of this study were submitted to the CINP International Meeting in Athens, Greece, taking place from 3rd to 5th October 2019.

Supplementary Material
======================

###### 

Click here for additional data file.
